January 29, 2008 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, announced the initiation of patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma... [PDF] TOPIGEN's Press Release-
Showing posts with label Topigen. Show all posts
Showing posts with label Topigen. Show all posts
Feb 14, 2008
TOPIGEN's TPI ASM8 , European Phase 2 Clinical Study of TPI ASM8 in Patients With Asthma
January 29, 2008 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, announced the initiation of patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma... [PDF] TOPIGEN's Press Release-
Nov 22, 2007
NicOx, TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020
November 20, 2007 - ...This new clinical study follows the recent announcement of promising top-line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be potentially beneficial in COPD (see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States... 
[PDF] NicOx' Press Release - PDF en Français - [PDF] Topigen's Press Release -
Sep 11, 2007
TOPIGEN Pharmaceuticals, TPI 1020 Into Phase 2 Development for COPD
September 10, 2007 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, announced the successful completion of a Phase 2a safety trial with TPI 1020 in smokers with asthma.TOPIGEN also announced plans to initiate a Phase 2 clinical trial of TPI 1020 in chronic obstructive pulmonary disease (COPD) in the second half of 2007.TPI 1020 is a novel anti-inflammatory respiratory drug licensed from NicOx S.A.
TOPIGEN Pharmaceuticals' Press Release -
Subscribe to:
Posts (Atom)
